Development and validation of clinical screening systems for Cushing disease in the United States.

ABSTRACT:

Purpose

Clinical screening systems (CSSs) for Cushing syndrome (CS) validated in Europe have not been evaluated for CS or Cushing disease (CD) in the United States (US). We aimed to evaluate existing CSSs in US patients and develop two new symptom-based CSSs to identify patients with high pre-test probability of disease warranting referral for definitive biochemical workup-one for broad CS screening and one specifically for CD.

Methods

Data were obtained from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID)-comprising 615 patients who underwent transnasal transsphenoidal resection for CD at one of 11 US pituitary centers, the Centers for Disease Control and Prevention's 2019 National Health Interview Survey (NHIS)-comprising 31,997 US respondents, and

SUBMITTER: Salcedo-Sifuentes JE 

PROVIDER: S-EPMC12513928 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature